Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Meets Estimates

Compass Therapeutics (NASDAQ:CMPX) issued its earnings results on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10), Zacks reports. The business had revenue of $0.85 million during the quarter.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $1.20 on Wednesday. The stock has a 50 day simple moving average of $1.05 and a 200 day simple moving average of $1.46. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.58. The firm has a market capitalization of $165.11 million, a PE ratio of -3.33 and a beta of 0.79.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Monday. Wedbush restated an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, August 7th.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.